BRPI0822095A2 - Método para reduzir o sangramento e/ou hematoma em um paciente - Google Patents

Método para reduzir o sangramento e/ou hematoma em um paciente

Info

Publication number
BRPI0822095A2
BRPI0822095A2 BRPI0822095-6A2A BRPI0822095A BRPI0822095A2 BR PI0822095 A2 BRPI0822095 A2 BR PI0822095A2 BR PI0822095 A BRPI0822095 A BR PI0822095A BR PI0822095 A2 BRPI0822095 A2 BR PI0822095A2
Authority
BR
Brazil
Prior art keywords
hematoma
patient
reducing bleeding
bleeding
reducing
Prior art date
Application number
BRPI0822095-6A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jack A Dejovin
Original Assignee
Galderma Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Lab Inc filed Critical Galderma Lab Inc
Publication of BRPI0822095A2 publication Critical patent/BRPI0822095A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
BRPI0822095-6A2A 2007-12-21 2008-12-17 Método para reduzir o sangramento e/ou hematoma em um paciente BRPI0822095A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1591207P 2007-12-21 2007-12-21
PCT/US2008/013797 WO2009082452A1 (en) 2007-12-21 2008-12-17 Pre-surgical treatment

Publications (1)

Publication Number Publication Date
BRPI0822095A2 true BRPI0822095A2 (pt) 2014-10-07

Family

ID=40801507

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822095-6A2A BRPI0822095A2 (pt) 2007-12-21 2008-12-17 Método para reduzir o sangramento e/ou hematoma em um paciente

Country Status (10)

Country Link
US (1) US20110224215A1 (enExample)
EP (1) EP2230910A4 (enExample)
JP (1) JP5580210B2 (enExample)
KR (1) KR20100099191A (enExample)
CN (1) CN101902913B (enExample)
AU (1) AU2008341112B2 (enExample)
BR (1) BRPI0822095A2 (enExample)
CA (1) CA2709199A1 (enExample)
NZ (1) NZ586302A (enExample)
WO (1) WO2009082452A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
EP2818184B1 (en) * 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura
WO2010136594A2 (en) 2009-05-29 2010-12-02 Symatese Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
RU2535008C2 (ru) 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
MX2012010824A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
CA2814975A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel composition
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
SG189896A1 (en) * 2010-10-21 2013-06-28 Galderma Sa Brimonidine gel compositions and methods of use
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
BR112014009210A2 (pt) 2011-10-19 2017-04-18 Galderma Sa método para a redução da vermelhidão facial cutânea
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
CA3079824A1 (en) * 2017-10-23 2019-05-02 Microcures, Inc. Method for enhancing recovery of cosmetic laser-treated skin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
EP2818184B1 (en) * 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura

Also Published As

Publication number Publication date
CN101902913B (zh) 2014-06-18
AU2008341112A1 (en) 2009-07-02
US20110224215A1 (en) 2011-09-15
EP2230910A4 (en) 2011-04-13
CA2709199A1 (en) 2009-07-02
NZ586302A (en) 2013-03-28
JP5580210B2 (ja) 2014-08-27
AU2008341112B2 (en) 2014-02-06
KR20100099191A (ko) 2010-09-10
CN101902913A (zh) 2010-12-01
JP2011507845A (ja) 2011-03-10
EP2230910A1 (en) 2010-09-29
WO2009082452A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
BRPI0822095A2 (pt) Método para reduzir o sangramento e/ou hematoma em um paciente
BRPI0819075A2 (pt) Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
BRPI0917711A2 (pt) método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
FI20085839A0 (fi) Menetelmiä ja välineitä pehmytkudosteknologiaan
BRPI0807918A2 (pt) composições e método para preservação de tecido
BRPI0921579A2 (pt) método para ligar dinamicamente programa em plataforma embutida e plataforma embutida
PT2209272E (pt) Dispositivos e métodos para o aumento de capacidade em comunicações sem fios
BRPI0807525A2 (pt) Dispositivo endo-cirúrgico e método
BRPI0907162A2 (pt) Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
BRPI0811996A2 (pt) Composição amaciante para tecido, e, método para amaciar um tecido
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BRPI0914035A2 (pt) ventilador e método para ventilar um paciente usando um ventilador
BRPI0910851A2 (pt) métodos e sistemas para protocolos de harq
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
BRPI0810806A2 (pt) Método para tratar uma lesão cutânea em um indivíduo
BRPI0905851A2 (pt) Métodos, sistemas, e dispositivos para realizar procedimentos eletrocirúrgicos
BRPI0917722A2 (pt) organismo transgênico e método para manipular o teor de malonatos em um organismo transgênico
BRPI0921959A2 (pt) métodos e composições para remoção de tatuagem
BRPI0910763A2 (pt) métodos e dispositivos para dissecção de tecidos
BRPI0821220A2 (pt) Composiçoes e métodos para reduzir ou prevenir perda de água da pele
BRPI0907227A2 (pt) Método e dispositivo para assinatura
BRPI0920419A2 (pt) pinça para o osso e a pele.
BRPI0915698A2 (pt) método para medir o conteúdo de água em um composto e dispositivo de medição de conteúdo de água
BRPI0823114A2 (pt) Dispositivo para cirurgias em prolapsos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]